Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept

Dermatologica Sinica

Volumn 31, Issue 1, 2013, Pages 11-18

  Wang, Ting Shun ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

adalimumab; biologics; etanercept; psoriasis; psoriasis area and severity index; switch

Indexed keywords

ADALIMUMAB; ADEFOVIR DIPIVOXIL; EFALIZUMAB; ETANERCEPT; LAMIVUDINE; METHOTREXATE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALE; NEVUS; OUTCOME ASSESSMENT; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84875747608     PISSN: 10278117     EISSN: 2223330X     Source Type: Journal    
DOI: 10.1016/j.dsi.2012.07.004     Document Type: Article

References (73)

1. R. Mössner, M.P. Schön, and K. Reich Tumor necrosis factor antagonists in the therapy of psoriasis Clin Dermatol 26 2008 486 502
2. J.M. Gelfand, J. Wan, and K. Callis Duffin Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting Arch Dermatol 148 2012 487 494
3. P.P. Van Lümig, L.L. Lecluse, and R.J. Driessen Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept Br J Dermatol 163 2010 838 846
4. C.L. Martyn-Simmons, L. Green, and G. Ash Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation J Eur Acad Dermatol Venereol 23 2009 1394 1397
5. L.L. Lecluse, M. de Groot, J.D. Bos, and P.I. Spuls Experience with biologics for psoriasis in daily practice: switching is worth a try Br J Dermatol 161 2009 948 951
6. C. Ryan, B. Kirby, P. Collins, and S. Rogers Adalimumab treatment for severe recalcitrant chronic plaque psoriasis Clin Exp Dermatol 34 2009 784 788
7. R.T. Woolf, C.H. Smith, K. Robertson, and J.N. Barker Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study Br J Dermatol 163 2010 889 892
8. M. Papoutsaki, M.S. Chimenti, and A. Costanzo Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275
9. J.P. Ortonne, S. Chimenti, and K. Reich Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE J Eur Acad Dermatol Venereol 25 2011 1012 1020
10. R. Vender An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab J Drugs Dermatol 10 2011 396 402
11. A.D. Ormerod Switching biologics for psoriasis Br J Dermatol 163 2010 667 669
12. C. Saccomani, S. Penz, and R. Guerre-Schmidt Biological therapy for psoriasis: practical experience at a French dermatology unit Ann Dermatol Venereol 136 2009 877 882
13. A. Mazzotta, M. Esposito, A. Costanzo, and S. Chimenti Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study Am J Clin Dermatol 10 2009 319 324
14. E. Lie, D. van der Heijde, and T. Uhlig Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register Ann Rheum Dis 70 2011 157 163
15. M. Blom, W. Kievit, and J. Fransen The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis J Rheumatol 36 2009 2171 2177
16. Y.H. Lee, J.D. Ji, and G.G. Song Tumor necrosis factor-alpha promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis J Rheumatol 34 2007 43 49
17. L. Padyukov, J. Lampa, and M. Heimburger Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis Ann Rheum Dis 62 2003 526 529
18. A. Kastbom, J. Bratt, and S. Ernestam Fc-gamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis Arthritis Rheum 56 2007 448 452
19. T.F. Tsai, and T.Y. Yeh The use of biologics for psoriasis in Asia-Pacific region Curr Rheumatol Rev 5 2009 149 152
20. H.Y. Chiu, T.S. Wang, Y.T. Cho, and T.F. Tsai Etanercept use for psoriasis in Taiwan: a case series study Int J Dermatol February 20, 2012 10.1111/j.1365-4632.2011.05273.x
21. K. Gordon, N. Korman, and E. Frankel Efficacy of etanercept in an integrated multistudy database of patients with psoriasis J Am Acad Dermatol 54 2006 S101 S111
22. A.B. Gottlieb, C.L. Leonardi, and B.S. Goffe Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database J Am Acad Dermatol 54 2006 S92 100
23. A.B. Gottlieb, R.T. Matheson, and N. Lowe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
24. C.L. Leonardi, J.L. Powers, and R.T. Matheson Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
25. K.A. Papp, S. Tyring, and M. Lahfa A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
26. S. Tyring, K.B. Gordon, and Y. Poulin Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
27. Wu YF, Huang YH. The efficacy and safety of etanercept in treating patients with recalcitrant psoriasis. 37th Annual Meeting of the Taiwanese Dermatological Association, November 26-27, 2011. Poster RR02. Taipei, Taiwan.
28. W. Sterry, J.P. Ortonne, and B. Kirkham Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double-blind multicenter trial BMJ 340 2010 Feb 2 c147 10.1136/bmj.c147
29. Tsai TF, Youn J, Foley P, et al. PRESTA: Asia-Pacific subanalysis; unpublished data presented at the Asian Academy of Dermatology and Venereology, November 6-7, 2009, Hanoi.
30. L.L. Lecluse, R.J. Driessen, and P.I. Spuls Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
31. K.A. Haitz, and R.E. Kalb Infliximab in the treatment of psoriasis in patients previously treated with etanercept J Am Acad Dermatol 57 2007 120 125
32. A. Asahina, H. Nakagawa, T. Etoh, and M. Ohtsuki Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study J Dermatol 37 2010 299 310
33. S. Noda, K. Mizuno, and M. Adachi Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital J Dermatol 39 2012 265 268
34. H.Y. Chiu, T.S. Wang, C.Y. Chung, and T.F. Tsai The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis J Eur Acad Dermatol Venereol 26 2012 991 998
35. E. Hjardem, M. Østergaard, and J. Pødenphant Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66 2007 1184 1189
36. M.C. Wick, S. Ernestam, and S. Lindblad Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34 2005 353 358
37. B. Haraoui, E.C. Keystone, and J.C. Thorne Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept J Rheumatol 31 2004 2356 2359
38. K.L. Hyrich, M. Lunt, and K.D. Watson Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 2007 13 20
39. A.N. Bennett, P. Peterson, and A. Zain Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure Rheumatology 44 2005 1026 1031
40. H.T. Ang, and S. Helfgott Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 30 2003 2315 2318
41. G. Cohen, N. Courvoisier, and J.D. Cohen The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis Clin Exp Rheumatol 23 2005 795 800
42. A. Finckh, A. Ciurea, and L. Brulhart Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69 2010 387 393
43. J.A. Karlsson, L.E. Kristensen, and M.C. Kapetanovic Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology 47 2008 507 513
44. R.F. Van Vollenhoven Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue Ann Rheum Dis 66 2007 849 851
45. F. Conti, F. Ceccarelli, and E. Marocchi Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period Ann Rheum Dis 66 2007 1393 1397
46. H.Y. Chiu, P.Y. Huang, and S.H. Jee Human leukocyte antigens polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis Br J Dermatol 166 2012 188 197
47. T.F. Tsai, C.Y. Hu, and W.L. Tsai HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan Arch Dermatol Res 194 2002 214 220
48. S.H. Jee, T.F. Tsai, and W.L. Tsai HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population Br J Dermatol 139 1998 978 983
49. J.H. Saurat, G. Stingl, and L. Dubertret Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
50. A. Asahina, H. Nakagawa, and T. Etoh Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study J Dermatol 37 2010 299 310
51. L.C. Zaba, I. Cardinale, and P. Gilleaudeau Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses J Exp Med 204 2007 3183 3194
52. Tyring S, Poulin Y, Langley R, et al. A 96-week phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006. Poster. San Francisco, CA, USA.
53. G.M. Bartelds, C.A. Wijbrandts, and M.T. Nurmohamed Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naïve patients: a cohort study Ann Rheum Dis 69 2010 817 821
54. A.W. Van Kuijk, M. de Groot, S.O. Stapel, B.A. Dijkmans, G.J. Wolbink, and P.P. Tak Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis Ann Rheum Dis 69 2010 624 625
55. A.D. Burden Drug survival rates for tumour necrosis factor-α antagonists in psoriasis Br J Dermatol 164 2011 940 941
56. H.S. Chen, M.P. Tseng, and T.F. Tsai An epidemiologic study of Taiwanese psoriatic patients in a single clinic Dermatol Sin 21 2003 216 224
57. J. Crowley Scalp psoriasis: an overview of the disease and available therapies J Drugs Dermatol 9 2010 912 918
58. S. Tyring, J. Bagel, and C. Lynde Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept J Eur Acad Dermatol Venereol December 21, 2011 10.1111/j.1468-3083.2011.04394.x
59. J. Bagel, C. Lynde, S. Tyring, G. Kricorian, Y. Shi, and P. Klekotka Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept J Am Acad Dermatol 67 2012 86 92
60. F. Wang, N. Smith, and L. Maier Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of IL-19, IL-20 and IL-24 Br J Dermatol 167 2012 92 102
61. J.J. Gomez-Reino, and L. Carmona BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 2006 R29 Epub 2006 Jan 6
62. M.C. Genovese, P.J. Mease, and G.T. Thomson Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J Rheumatol 34 2007 1040 1050
63. C.E. Antoni, A. Kavanaugh, and B. Kirkham Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 52 2005 1227 1236
64. P.J. Mease, A.J. Kivitz, and F.X. Burch Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 2004 2264 2272
65. P.J. Mease, D.D. Gladman, and C.T. Ritchlin Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 2005 3279 3289
66. T. Bhutani, and J. Koo Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series J Dermatol Treat 22 2011 75 78
67. A. Migliore, E. Bizzi, S. Broccoli, and B. Laganà Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator Clin Rheumatol 31 2012 133 137
68. S. Bombardieri, A.A. Ruiz, P. Fardellone Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNFantagonist therapy in clinical practice Rheumatology 46 2007 1191 1199
69. T.F. Tsai, T.S. Wang, and S.T. Hung Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan J Dermatol Sci 63 2011 40 46
70. Y.T. Cho, C.H. Chen, H.Y. Chiu, and T.F. Tsai Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan J Dermatol 39 2012 269 273
71. H.E. Kohrt, D.L. Ouyang, and E.B. Keeffe Antiviral prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection Clin Liver Dis 11 2007 965 991
72. M.B. Carroll, and M.A. Forgione Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action Clin Rheumatol 29 2010 1021 1029
73. D.L. Scott, and G.H. Kingsley Tumor necrosis factor inhibitors for rheumatoid arthritis N Engl J Med 355 2006 704 712